Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: A prospective study

Psychiatry Investigation

Volumn 10, Issue 2, 2013, Pages 148-154

  Beyazyüz, Murat ^a   Albayrak, Yakup ^b   Eǧilmez, Oǧuzhan Bekir ^c   Albayrak, Neslihan ^b   Beyazyüz, Elmas ^d  

^a Golbasi Hasvak State Hospital   (Turkey)

^b Kirklareli State Hospital   (Turkey)

^c Adiyaman Devlet Hastanesi   (Turkey)

^d ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anxiety; Metabolic syndrome; Prospective; Side effect; SSRI

Indexed keywords

CHOLESTEROL; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMORBIDITY; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; WAIST CIRCUMFERENCE;

EID: 84879394885     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2013.10.2.148     Document Type: Article

References (53)

1. Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998;55:310-316.
2. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Antidepressant prescribing patterns: a comparison of blacks and whites in a medicaid population. Clin Drug Investig 1998;16:135-140.
3. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002;14:175-182.
4. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-1176.
5. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991;24:62-67.
6. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-636.
7. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33:351-375.
8. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004;61:1107-1115.
9. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-98.
10. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
11. Sussman N, Ginsberg D. Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain. Psychiatr Ann 1998;28:89-97.
12. Mackle MKJ, Kocsis J. Effects on body weifght of the SSRI citalopram. Las Croabas, Puerto Rico: Scientific abstract of the 37th Annual Meeting of the American College of Neuropsychopharmacology, Dec 14-18, 1998.
13. Bouver CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996;11:273-278.
14. Bailey DL, Melledo JM. Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder. J Clin Psychopharmacol 2003;23:317-319.
15. Kim EJ, Yu BH. Increased cholesterol levels after paroxetine treatment in patients with panic disorder. J Clin Psychopharmacol 2005;25:597-599.
16. Pine DS, Goldstein RB, Wolk S, Weissman MM. The association between childhood depression and adulthood body mass index. Pediat rics 2001;107:1049-1056.
17. Berlin I, Lavergne F. Relationship between body-mass index and depressive symptoms in patients with major depression. Eur Psychiatry 2003;18:85-88.
18. Reader MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia and diabetes with selective serotonin reuptake inhibitors: the Hordaland health study. J Clin Psychiatry 2006;67:1974-1982.
19. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004;66:316-322.
20. Lehto SM, Heiskanen T, Hintikka J, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, et al. Metabolic syndrome-the impact of depression. Ann Epidemiol 2008;18:871.
21. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 2008;69: 178-182.
22. Vanhala M, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Koponen H. Depressive symptoms predispose females to metabolic syndrome: a 7-year follow-up study. Acta Psychiatr Scand 2008;119:137-142.
23. Dunbar JA, Reddy P, Davis-Lameloise N, Philpot B, Laatikainen T, Kilkkinen A, et al. Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care 2008;31:2368-2373.
24. Miettola J, Niskanen LK, Viinamaki H, Kumpusalo E. Metabolic syndrome is associated with self-perceived depression. Scand J Prim Health Care 2008;26:203-210.
25. Muhtz C, Zyriax BC, Klahn T, Windler E, Otte C. Depressive symptoms and metabolic risk: effects of cortisol and gender. Psychoneuroendocrinology 2009;34:1004-1011.
26. Hildrum B, Mykletun A, Midthjell K, Ismail K, Dahl AA. No association of depression and anxiety with the metabolic syndrome: the Norwegian HUNT study. Acta Psychiatr Scand 2009;120:14-22.
27. Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 2007;62: 1251-1257.
28. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002;51:1573-1577.
29. Carroll D, Phillips AC, Thomas GN, Gale CR, Deary I, Batty GD. Generalized anxiety disorder is associated with metabolic syndrome in the Vietnam experience study. Biol Psychiatry 2009;66:91-93.
30. American Psychiatric Assosiation. Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition, Text Revsion. Washington DC: American Psychiatric Assosiation; 2000.
31. World Health Organization (WHO). The Composite International Diagnostic Interview (CIDI). Geneva: WHO; 1997.
32. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
33. Yazi{dotless}ci{dotless} MK, Başaran D, Tanri{dotless}verdi N ve ark. Hamilton Anksiyete Deǧer-lendirme Ölçeǧi, deǧerlendiriciler arasi{dotless} güvenilirlik ve geçerlik çali{dotless}şmasi{dotless}. Türk Psikiyatri Dergisi 1998;9:114-117.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
35. Akdemir A, Orsel SD, Dag I, Turkcapar MH, Iscan N, Ozbay H. The validity and reliability of the Hamilton Depression Rating Scale and its clinical use. Psikiyatri Psikol Psikofarmakol Derg 1996;4:251-259.
36. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
37. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
38. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-2449.
39. Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300:2379-2388.
40. Phelan M, Seller J, Leese M. The routine assessment of severity amongst people with mental illness. Soc Psychiatry Psychiatr Epidemiol 2001;36: 200-206.
41. Lesage AD, Goering P, Lin E. Family physicians and the mental health system. Report from the Mental Health Supplement to the Ontario Health Survey. Can Fam Physician 1997;43:251-256.
42. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217.
43. Mast BT, Neufeld S, MacNeill SE, Lichtenberg PA. Longitudinal support for the relationship between vascular risk factors and late-life depressive symptoms. Am J Geriatr Psychiatry 2004;12:93-101.
44. Davidson JR, Miller RD, Turnbull CD, Sullivan JL. Atypical depression. Arch Gen Psychiatry 1982;39:527-534.
45. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-3285.
46. Katon WJ, Russo JE, Von Korff M, Lin EH, Ludman E, Ciechanowski PS. Long-term effects on medical costs of improving depression outcomes in patients with depression and diabetes. Diabetes Care 2008; 31:1155-1159.
47. Ye Z, Chen L, Yang Z, Li Q, Huang Y, He M, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS One 2011;6:e21551.
48. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867.
49. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-1272.
50. Wilsgaard T, Jacobsen BK. Lifestyle factors and incident metabolic syndrome The Tromso Study 1979-2001. Diabetes Res Clin Pract 2007;78: 217-224.
51. Santos AC, Ebrahim S, Barros H. Alcohol intake, smoking, sleeping hours, physical activity and the metabolic syndrome. Prev Med 2007; 44:328-334.
52. Katano S, Nakamura Y, Nakamura A, Murakami Y, Tanaka T, Nakagawa H, et al. Relationship among physical activity, smoking, drinking and clustering of the metabolic syndrome diagnostic components. J Atheroscler Thromb 2010;17:644-650.
53. Cai H, Huang J, Xu G, Yang Z, Liu M, Mi Y, et al. Prevalence and determinants of metabolic syndrome among women in Chinese rural areas. PLoS One 2012;7:e36936.